Company intelligence / Profile preview
Maijin Biomedical Technology
上海（Shanghai）, 上海市（Shanghai）, 中国（China）mabgenbiotech.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Maijin Biomedical Technology has a pipeline focused on immunology and autoimmune disorders. Its lead assets include izokibep for plaque psoriasis in Phase 3, IMG‑016 for thrombocytopenia in Phase 3, and several other biologics targeting immune pathways in earlier clinical stages. The company is advancing multiple monoclonal antibodies and bispecifics through clinical trials.
- Therapeutic areas
- DermatologyImmunologyHematology
- Modalities
- Monoclonal antibodySmall moleculeFusion proteinBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Affibody AB [izokibep development partnership]Inmagene Biopharmaceuticals [collaborative development noted]
Beyond the preview
Go deeper on Maijin Biomedical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Maijin Biomedical Technology.